India, Oct. 28 -- Shares of Genmab A/S (GMAB) are rising 30 percent on Wednesday morning after the company announced positive topline results from the global Phase 3 LiGeR-HN1 trial for patients with first-line PD-L1 positive recurrent/metastatic head and neck squamous cell carcinoma.
The company's shares are currently trading at $58.15 on the Nasdaq, up 30.19 percent. The stock opened at $44.64 and has climbed as high as $57.60 so far in today's session. Over the past year, it has traded in a range of $23.62 to $57.60.
For comments and feedback contact: editorial@rttnews.com
Published by HT Digital Content Services with permission from RTT News....